LOW-DOSE CYCLOSPORINE-A VERSUS PULSED CYCLOPHOSPHAMIDE IN BEHCETS-SYNDROME - A SINGLE MASKED TRIAL


Creative Commons License

OZYAZGAN Y. , YURDAKUL S. , YAZICI H., TUZUN B., ISCIMEN A., TUZUN Y., ...More

BRITISH JOURNAL OF OPHTHALMOLOGY, vol.76, no.4, pp.241-243, 1992 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 76 Issue: 4
  • Publication Date: 1992
  • Doi Number: 10.1136/bjo.76.4.241
  • Title of Journal : BRITISH JOURNAL OF OPHTHALMOLOGY
  • Page Numbers: pp.241-243

Abstract

A single masked trial of cyclosporin A 5 mg/kg/day versus monthly 1 g intravenous boluses of cyclophosphamide was conducted among 23 patients with Behcet's syndrome and active, potentially reversible uveitis. The trial was unmasked after a mean of 12 (SD 2) months for the cyclosporin A group (n = 12) and a mean of 10 (SD 3) months for the cyclophosphamide group (n = 11). During the initial 6 months the visual acuity significantly improved (p < 0.001) in the cyclosporin A group whereas this was not observed in the cyclophosphamide group. The subsequent follow-up of patients up to 24 months suggested that the initial improvement in visual acuity with cyclosporin A was not sustained. More extensive and especially long-term studies of cyclosporin A in the uveitis of Behcet's syndrome are warranted.